Ishii Taeko, Saeki Yukihiko
Department of Molecular Medicine, Graduate School of Medicine, Osaka University.
Nihon Rinsho. 2002 Mar;60(3):551-5.
Rheumatoid arthritis(RA) is a systemic chronic inflammatory disease characterized by destructive polyarthritis. Although its etiology and pathogenesis are still to be elucidated, recent cumulative evidence has suggested both T cells and proinflammatory cytokines (such as tumor necrosis factor(TNF)-alpha, interleukin(IL)-1, IL-6) play pivotal roles in the pathogenesis. Therefore, they are thought to be optimal therapeutic targets. In fact, new therapies targeted to T cells and proinflammatory cytokines using biological agents including monoclonal antibodies have been developed extensively. Among them, anti-proinflammatory cytokine therapies, such as anti-TNF-alpha therapy, have shown an excellent efficacy and some are currently accepted as a new promising therapy for RA. It is expected that further investigation will provide additional insights into cure of RA.
类风湿关节炎（RA）是一种以破坏性多关节炎为特征的全身性慢性炎症性疾病。尽管其病因和发病机制仍有待阐明，但最近积累的证据表明，T细胞和促炎细胞因子（如肿瘤坏死因子（TNF）-α、白细胞介素（IL）-1、IL-6）在发病机制中起关键作用。因此，它们被认为是最佳治疗靶点。事实上，针对T细胞和促炎细胞因子的新型生物制剂疗法，包括单克隆抗体，已得到广泛发展。其中，抗促炎细胞因子疗法，如抗TNF-α疗法，已显示出卓越疗效，目前一些疗法已被公认为是治疗RA的新的有前景的疗法。预计进一步的研究将为RA的治愈提供更多见解。
